Abbott Laboratories (ABT) Q2 FY2026 Financial Statements: Revenue $12.59B, Net income $928.00M
More for Abbott Laboratories: Company index · 10-K and 10-Q summary · 8-K filings and events
PeriodQ2 FY2026
Published
Abbott Laboratories reported $12.59 billion in net sales for Q2 FY2026, the quarter ended June 30, 2026, up 13.0% from a year earlier, as the Exact Sciences cancer diagnostics business acquired in March 2026 added to the Diagnostic Products segment. Earnings moved the other way: net earnings were $928 million, down 47.8%, and diluted EPS was $0.53 against $1.01 a year earlier, with acquisition-related intangible amortization, integration expense, higher legal reserves, interest on the debt raised for the acquisition and a higher tax charge all weighing on the result. Operating earnings were $1.69 billion, down 17.5%, while Medical Devices, Abbott's largest segment, had sales of $5.85 billion, up 9.0%.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $12,593,000,000 | up 13.0% |
| Net income | $928,000,000 | down 47.8% |
| Diluted EPS | $0.53 | down 47.5% |
| Operating earnings | $1,693,000,000 | down 17.5% |
| Medical Devices sales | $5,853,000,000 | up 9.0% |
About this file
| Ticker | ABT |
|---|---|
| CIK | 0000001800 |
| Company | Abbott Laboratories |
| Business type | industrial |
| Schema template | standard (revenue / operating earnings / net earnings; balance sheet; cash flow) |
| Schema rationale | Abbott is a diversified healthcare products manufacturer selling branded generic pharmaceuticals, nutritionals, diagnostics and medical devices. The standard manufacturer template fits: net sales, cost of products sold, operating earnings, net earnings and per-share amounts, with a balance sheet and a cash flow statement. Abbott reports cost of products sold EXCLUDING amortization of acquired intangibles and does not print a gross profit line, so none is stated here; the two cost lines are reported separately exactly as the filings present them. Segment net sales and segment operating earnings are carried alongside because Abbott manages and reports the business in four segments. |
| Reporting currency | USD |
| Converted to USD | no |
| Units | actual dollars (not millions) |
| Fiscal calendar note | Abbott's fiscal year is the calendar year, ending December 31. Quarters end March 31, June 30, September 30 and December 31. |
ABT annual income statement, balance sheet and cash flow
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Fiscal year | 2025 | 2024 | 2023 |
| Label | FY2025 | FY2024 | FY2023 |
| Period start | 2025-01-01 | 2024-01-01 | 2023-01-01 |
| Period end | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Period type | fiscal year | fiscal year | fiscal year |
| Source accession | 0001628280-26-010185 | 0001628280-26-010185 | 0001628280-26-010185 |
| Source form | 10-K filed 2026-02-20 | 10-K filed 2026-02-20 | 10-K filed 2026-02-20 |
| Income statement | |||
| Net sales | 44,328,000,000 | 41,950,000,000 | 40,109,000,000 |
| Cost of products sold excluding amortization | 19,319,000,000 | 18,706,000,000 | 17,975,000,000 |
| Amortization of intangible assets | 1,682,000,000 | 1,878,000,000 | 1,966,000,000 |
| Research and development | 2,942,000,000 | 2,844,000,000 | 2,741,000,000 |
| Selling general and administrative | 12,332,000,000 | 11,697,000,000 | 10,949,000,000 |
| Total operating cost and expenses | 36,275,000,000 | 35,125,000,000 | 33,631,000,000 |
| Operating earnings | 8,053,000,000 | 6,825,000,000 | 6,478,000,000 |
| Interest expense | 493,000,000 | 559,000,000 | 637,000,000 |
| Interest income | -308,000,000 | -344,000,000 | -385,000,000 |
| Net foreign exchange gain loss | -50,000,000 | -27,000,000 | 41,000,000 |
| Other income expense net | -548,000,000 | -376,000,000 | -479,000,000 |
| Earnings before taxes | 8,466,000,000 | 7,013,000,000 | 6,664,000,000 |
| Taxes on earnings | 1,942,000,000 | -6,389,000,000 | 941,000,000 |
| Net earnings | 6,524,000,000 | 13,402,000,000 | 5,723,000,000 |
| Basic EPS | 3.73 | 7.67 | 3.28 |
| Diluted EPS | 3.72 | 7.64 | 3.26 |
| Basic shares | 1,741,000,000 | 1,740,000,000 | 1,740,000,000 |
| Diluted shares | 1,748,000,000 | 1,748,000,000 | 1,749,000,000 |
| Segment results | |||
| Established pharmaceuticals | |||
| Net sales | 5,536,000,000 | 5,194,000,000 | 5,066,000,000 |
| Operating earnings | 1,290,000,000 | 1,233,000,000 | 1,206,000,000 |
| Nutritional products | |||
| Net sales | 8,451,000,000 | 8,413,000,000 | 8,154,000,000 |
| Operating earnings | 1,558,000,000 | 1,505,000,000 | 1,333,000,000 |
| Diagnostic products | |||
| Net sales | 8,937,000,000 | 9,341,000,000 | 9,988,000,000 |
| Operating earnings | 1,740,000,000 | 2,073,000,000 | 2,433,000,000 |
| Medical devices | |||
| Net sales | 21,387,000,000 | 18,986,000,000 | 16,887,000,000 |
| Operating earnings | 7,212,000,000 | 6,153,000,000 | 5,306,000,000 |
| Total reportable segments | |||
| Net sales | 44,311,000,000 | 41,934,000,000 | 40,095,000,000 |
| Operating earnings | 11,800,000,000 | 10,964,000,000 | 10,278,000,000 |
| Balance sheet | |||
| Cash and equivalents | 8,522,000,000 | 7,616,000,000 | |
| Short term investments | 417,000,000 | 351,000,000 | |
| Trade receivables net | 7,929,000,000 | 6,925,000,000 | |
| Total inventories | 6,488,000,000 | 6,194,000,000 | |
| Total current assets | 25,996,000,000 | 23,656,000,000 | |
| Net property and equipment | 11,816,000,000 | 10,658,000,000 | |
| Intangible assets net | 5,526,000,000 | 6,647,000,000 | |
| Goodwill | 24,035,000,000 | 23,108,000,000 | |
| Total assets | 86,713,000,000 | 81,414,000,000 | |
| Current portion of long term debt | 3,033,000,000 | 1,500,000,000 | |
| Total current liabilities | 16,496,000,000 | 14,157,000,000 | |
| Long term debt | 9,896,000,000 | 12,625,000,000 | |
| Post employment and other long term liabilities | 7,550,000,000 | 6,731,000,000 | |
| Total abbott shareholders investment | 52,130,000,000 | 47,664,000,000 | |
| Noncontrolling interests | 641,000,000 | 237,000,000 | |
| Total equity | 52,771,000,000 | 47,901,000,000 | |
| Total debt | 12,929,000,000 | 14,125,000,000 | |
| Total liabilities | 33,942,000,000 | 33,513,000,000 | |
| Cash flow | |||
| Depreciation | 1,434,000,000 | 1,340,000,000 | 1,277,000,000 |
| Amortization of intangible assets | 1,682,000,000 | 1,878,000,000 | 1,966,000,000 |
| Share based compensation | 664,000,000 | 673,000,000 | 644,000,000 |
| Operating cash flow | 9,566,000,000 | 8,558,000,000 | 7,261,000,000 |
| Acquisitions of businesses and technologies net of cash | -105,000,000 | 0 | -877,000,000 |
| Investing cash flow | -2,422,000,000 | -2,338,000,000 | -3,133,000,000 |
| Financing cash flow | -6,309,000,000 | -5,404,000,000 | -7,091,000,000 |
| Cash and equivalents end of period | 8,522,000,000 | 7,616,000,000 | 6,896,000,000 |
| Capital expenditures | 2,171,000,000 | 2,207,000,000 | 2,202,000,000 |
| Dividends paid | 4,116,000,000 | 3,836,000,000 | 3,556,000,000 |
| Purchases of common shares | 893,000,000 | 1,295,000,000 | 1,227,000,000 |
| Free cash flow | 7,395,000,000 | 6,351,000,000 | 5,059,000,000 |
ABT quarterly income statement, balance sheet and cash flow
| Q2 2026 | Q2 2025 | |
|---|---|---|
| Fiscal year | 2026 | 2025 |
| Fiscal quarter | 2 | 2 |
| Label | Q2 2026 | Q2 2025 |
| Period start | 2026-04-01 | 2025-04-01 |
| Period end | 2026-06-30 | 2025-06-30 |
| Period type | three months | three months |
| Source accession | 0001628280-26-050134 | 0001628280-26-050134 |
| Source form | 10-Q filed 2026-07-28 | 10-Q filed 2026-07-28 |
| Income statement | ||
| Net sales | 12,593,000,000 | 11,142,000,000 |
| Cost of products sold excluding amortization | 5,325,000,000 | 4,854,000,000 |
| Amortization of intangible assets | 658,000,000 | 420,000,000 |
| Research and development | 892,000,000 | 725,000,000 |
| Selling general and administrative | 4,025,000,000 | 3,091,000,000 |
| Total operating cost and expenses | 10,900,000,000 | 9,090,000,000 |
| Operating earnings | 1,693,000,000 | 2,052,000,000 |
| Interest expense | 351,000,000 | 121,000,000 |
| Interest income | -52,000,000 | -71,000,000 |
| Net foreign exchange gain loss | 4,000,000 | -11,000,000 |
| Other income expense net | -134,000,000 | -137,000,000 |
| Earnings before taxes | 1,524,000,000 | 2,150,000,000 |
| Taxes on earnings | 596,000,000 | 371,000,000 |
| Net earnings | 928,000,000 | 1,779,000,000 |
| Basic EPS | 0.53 | 1.02 |
| Diluted EPS | 0.53 | 1.01 |
| Basic shares | 1,740,420,000 | 1,743,437,000 |
| Diluted shares | 1,742,981,000 | 1,750,835,000 |
| Segment results | ||
| Established pharmaceuticals | ||
| Net sales | 1,499,000,000 | 1,383,000,000 |
| Operating earnings | 382,000,000 | 346,000,000 |
| Nutritional products | ||
| Net sales | 2,144,000,000 | 2,212,000,000 |
| Operating earnings | 368,000,000 | 418,000,000 |
| Diagnostic products | ||
| Net sales | 3,092,000,000 | 2,173,000,000 |
| Operating earnings | 499,000,000 | 372,000,000 |
| Medical devices | ||
| Net sales | 5,853,000,000 | 5,369,000,000 |
| Operating earnings | 1,969,000,000 | 1,796,000,000 |
| Total reportable segments | ||
| Net sales | 12,588,000,000 | 11,137,000,000 |
| Operating earnings | 3,218,000,000 | 2,932,000,000 |
| Balance sheet | ||
| Cash and equivalents | 5,104,000,000 | |
| Short term investments | 499,000,000 | |
| Trade receivables net | 8,599,000,000 | |
| Total inventories | 7,315,000,000 | |
| Total current assets | 24,517,000,000 | |
| Net property and equipment | 12,812,000,000 | |
| Intangible assets net | 17,211,000,000 | |
| Goodwill | 35,244,000,000 | |
| Total assets | 109,215,000,000 | |
| Current portion of long term debt | 3,005,000,000 | |
| Total current liabilities | 17,814,000,000 | |
| Long term debt | 29,603,000,000 | |
| Post employment and other long term liabilities | 10,036,000,000 | |
| Total abbott shareholders investment | 51,110,000,000 | |
| Noncontrolling interests | 652,000,000 | |
| Total equity | 51,762,000,000 | |
| Total debt | 32,608,000,000 | |
| Total liabilities | 57,453,000,000 | |
ABT year-to-date income statement and cash flow
| Six months ended June 30, 2026 | |
|---|---|
| Label | Six months ended June 30, 2026 |
| Period start | 2026-01-01 |
| Period end | 2026-06-30 |
| Period type | six months |
| Source accession | 0001628280-26-050134 |
| Source form | 10-Q filed 2026-07-28 |
| Income statement | |
| Net sales | 23,757,000,000 |
| Cost of products sold excluding amortization | 10,215,000,000 |
| Amortization of intangible assets | 1,080,000,000 |
| Research and development | 1,659,000,000 |
| Selling general and administrative | 7,765,000,000 |
| Total operating cost and expenses | 20,719,000,000 |
| Operating earnings | 3,038,000,000 |
| Interest expense | 525,000,000 |
| Interest income | -158,000,000 |
| Net foreign exchange gain loss | -9,000,000 |
| Other income expense net | -293,000,000 |
| Earnings before taxes | 2,973,000,000 |
| Taxes on earnings | 968,000,000 |
| Net earnings | 2,005,000,000 |
| Basic EPS | 1.15 |
| Diluted EPS | 1.14 |
| Basic shares | 1,741,438,000 |
| Diluted shares | 1,745,014,000 |
| Segment results | |
| Established pharmaceuticals | |
| Net sales | 2,925,000,000 |
| Operating earnings | 747,000,000 |
| Nutritional products | |
| Net sales | 4,161,000,000 |
| Operating earnings | 679,000,000 |
| Diagnostic products | |
| Net sales | 5,272,000,000 |
| Operating earnings | 834,000,000 |
| Medical devices | |
| Net sales | 11,392,000,000 |
| Operating earnings | 3,862,000,000 |
| Total reportable segments | |
| Net sales | 23,750,000,000 |
| Operating earnings | 6,122,000,000 |
| Cash flow | |
| Operating cash flow | 3,803,000,000 |
| Capital expenditures | 896,000,000 |
| Acquisitions of businesses and technologies net of cash | -19,962,000,000 |
| Investing cash flow | -20,997,000,000 |
| Financing cash flow | 13,795,000,000 |
| Dividends paid | 2,200,000,000 |
| Purchases of common shares | 1,225,000,000 |
| Depreciation | 783,000,000 |
| Amortization of intangible assets | 1,080,000,000 |
| Share based compensation | 485,000,000 |
| Cash and equivalents end of period | 5,104,000,000 |
| Free cash flow | 2,907,000,000 |
| Prior year comparative | |
| Label | Six months ended June 30, 2025 |
| Period start | 2025-01-01 |
| Period end | 2025-06-30 |
| Period type | six months |
| Source accession | 0001628280-26-050134 |
| Source form | 10-Q filed 2026-07-28 |
| Income statement | |
| Net sales | 21,500,000,000 |
| Cost of products sold excluding amortization | 9,322,000,000 |
| Amortization of intangible assets | 840,000,000 |
| Research and development | 1,441,000,000 |
| Selling general and administrative | 6,152,000,000 |
| Total operating cost and expenses | 17,755,000,000 |
| Operating earnings | 3,745,000,000 |
| Interest expense | 252,000,000 |
| Interest income | -153,000,000 |
| Net foreign exchange gain loss | -18,000,000 |
| Other income expense net | -264,000,000 |
| Earnings before taxes | 3,928,000,000 |
| Taxes on earnings | 824,000,000 |
| Net earnings | 3,104,000,000 |
| Basic EPS | 1.78 |
| Diluted EPS | 1.77 |
| Basic shares | 1,741,348,000 |
| Diluted shares | 1,749,054,000 |
| Segment results | |
| Established pharmaceuticals | |
| Net sales | 2,643,000,000 |
| Operating earnings | 644,000,000 |
| Nutritional products | |
| Net sales | 4,358,000,000 |
| Operating earnings | 812,000,000 |
| Diagnostic products | |
| Net sales | 4,227,000,000 |
| Operating earnings | 731,000,000 |
| Medical devices | |
| Net sales | 10,264,000,000 |
| Operating earnings | 3,405,000,000 |
| Total reportable segments | |
| Net sales | 21,492,000,000 |
| Operating earnings | 5,592,000,000 |
| Cash flow | |
| Operating cash flow | 3,464,000,000 |
| Capital expenditures | 986,000,000 |
| Acquisitions of businesses and technologies net of cash | -30,000,000 |
| Investing cash flow | -1,052,000,000 |
| Financing cash flow | -3,152,000,000 |
| Dividends paid | 2,055,000,000 |
| Purchases of common shares | 286,000,000 |
| Depreciation | 693,000,000 |
| Amortization of intangible assets | 840,000,000 |
| Share based compensation | 431,000,000 |
| Cash and equivalents end of period | 6,951,000,000 |
| Free cash flow | 2,478,000,000 |
ABT trailing twelve month income statement and cash flow
| Trailing twelve months ended June 30, 2026 | |
|---|---|
| Label | Trailing twelve months ended June 30, 2026 |
| Period start | 2025-07-01 |
| Period end | 2026-06-30 |
| Period type | trailing twelve months |
| Source accession | 0001628280-26-050134 |
| Source form | derived from the 10-Q filed 2026-07-28 and the 10-K filed 2026-02-20 |
| Income statement | |
| Net sales | 46,585,000,000 |
| Cost of products sold excluding amortization | 20,212,000,000 |
| Amortization of intangible assets | 1,922,000,000 |
| Research and development | 3,160,000,000 |
| Selling general and administrative | 13,945,000,000 |
| Total operating cost and expenses | 39,239,000,000 |
| Operating earnings | 7,346,000,000 |
| Interest expense | 766,000,000 |
| Interest income | -313,000,000 |
| Net foreign exchange gain loss | -41,000,000 |
| Other income expense net | -577,000,000 |
| Earnings before taxes | 7,511,000,000 |
| Taxes on earnings | 2,086,000,000 |
| Net earnings | 5,425,000,000 |
| Diluted shares | 1,745,980,000 |
| Diluted EPS | 3.11 |
| Cash flow | |
| Operating cash flow | 9,905,000,000 |
| Capital expenditures | 2,081,000,000 |
| Dividends paid | 4,261,000,000 |
| Purchases of common shares | 1,832,000,000 |
| Depreciation | 1,524,000,000 |
| Free cash flow | 7,824,000,000 |
Adjustments
| Value | |
|---|---|
| Splits applied | none |
| ADR ratio | n/a |
| FX | None. Abbott reports in U.S. dollars, so no currency conversion was applied. |
Notes
- Annual figures for 2025, 2024 and 2023 come from Abbott's Form 10-K for the year ended December 31, 2025 (accession 0001628280-26-010185). That filing's statement of earnings and statement of cash flows each present three years; the balance sheet presents only December 31, 2025 and December 31, 2024. FY2023 therefore carries an income statement and a cash flow statement here but no balance sheet.
- Quarterly, six-month and June 30, 2026 balance sheet figures come from Abbott's Form 10-Q for the quarter ended June 30, 2026 (accession 0001628280-26-050134). The quarterly list holds only the two discrete three-month periods that filing prints (the second quarter of 2026 and the second quarter of 2025); its six-month columns are kept separately under year_to_date so a cumulative figure is never read as a quarter. The 10-Q presents a balance sheet only at June 30, 2026 (with December 31, 2025 as the comparative), so the second quarter of 2025 carries no balance sheet.
- Abbott reports cost of products sold EXCLUDING amortization of intangible assets, and presents no gross profit subtotal. None is stated here; the two cost lines are carried separately, exactly as the statements print them.
- Abbott presents interest expense, interest (income), net foreign exchange (gain) loss and other (income) expense, net as deductions inside the expense stack below operating earnings, printing income amounts in parentheses. Those lines are carried here on that same basis, so a negative value denotes income: interest_income of -$308 million for fiscal 2025 and -$52 million for the second quarter of 2026 each mean interest INCOME of that amount, not a loss. Keeping the filing's signs is what lets operating earnings less these four lines reconcile to earnings before taxes in every period shown.
- Abbott's balance sheet prints no total liabilities line. The total liabilities figure here is the sum of total current liabilities, long-term debt, and post-employment obligations, deferred income taxes and other long-term liabilities; it ties to total assets less total shareholders' investment in each period shown. Total debt is the current portion of long-term debt plus long-term debt, as printed on the balance sheet.
- Abbott publishes no free cash flow figure. Free cash flow here is net cash from operating activities less acquisitions of property and equipment, which is the only capital expenditure line the cash flow statements show.
- The 10-Q's cash flow statement is presented for the six months ended June 30 only, and Abbott's second-quarter earnings release contains no cash flow statement. No discrete three-month cash flow is published, so neither quarterly entry carries a cash flow block; the six-month cash flows sit under year_to_date.
- The trailing-twelve-month view is derived, not filed: fiscal 2025 plus the six months ended June 30, 2026, less the six months ended June 30, 2025. Its diluted EPS is trailing net earnings divided by an implied trailing weighted average diluted share count of about 1,746.0 million, rolled forward the same way. Abbott does not publish either figure.
- On March 23, 2026, Abbott completed the acquisition of Exact Sciences Corporation for approximately $20.6 billion, paying $105 per share in cash, funded primarily by $20.0 billion of long-term debt issued in March 2026. The purchase price allocation is preliminary. This is what moves the June 30, 2026 balance sheet against December 31, 2025: goodwill from $24.0 billion to $35.2 billion, intangible assets from $5.5 billion to $17.2 billion and long-term debt from $9.9 billion to $29.6 billion, with $19,962 million of acquisitions of businesses and technologies in investing activities for the six months. Abbott also assumed about $2.8 billion of Exact Sciences debt, nearly all repaid by June 30, 2026. Exact Sciences contributed roughly $1.0 billion of net sales in the first six months of 2026 and is reported inside the Diagnostic Products segment as Cancer Diagnostics.
- Second-quarter 2026 net sales rose 13.0 percent from a year earlier while net earnings fell to $928 million from $1,779 million. On the face of the statement of earnings the cost lines that moved most were amortization of intangible assets ($658 million against $420 million), selling, general and administrative expense ($4,025 million against $3,091 million) and interest expense ($351 million against $121 million). The 10-Q attributes the rise in interest expense primarily to interest on debt incurred for the Exact Sciences acquisition.
- Fiscal 2024's taxes on earnings is a net BENEFIT of $6,389 million rather than an expense, which is why FY2024 net earnings of $13,402 million exceed pre-tax earnings of $7,013 million. The 10-K attributes this to $7.5 billion of non-cash valuation allowance adjustments following the restructuring of certain foreign affiliates and the confirmation of certain tax filing positions. FY2024 net earnings and EPS are not comparable with FY2023 or FY2025 on that basis.
- Segment figures are prepared on Abbott's internal management-reporting basis and are explicitly not presented in accordance with generally accepted accounting principles. Segment operating earnings exclude intangible asset amortization, corporate functions and benefit costs, net interest, share-based compensation and other net items, so they do not sum to consolidated operating earnings. Reportable-segment net sales also exclude a small 'Other' amount ($17 million in 2025; $5 million in the second quarter of 2026), so the segment total sits just below consolidated net sales.
- Share counts are recorded in actual shares. The 10-K's statement of earnings states shares in millions and the 10-Q's states them in thousands; both were converted here.
- No stock split, currency conversion or ADS adjustment applies. Abbott has not split its common stock in the years covered here, reports in U.S. dollars, and is a domestic filer whose common shares trade directly.
Uncertainties
- No discrete three-month cash flow figure exists for either quarter shown. Abbott's 10-Q presents cash flows cumulatively for the six months, and the second-quarter earnings release furnished on Form 8-K contains no cash flow statement. A quarterly operating or free cash flow figure could not be read from any filing and is therefore absent rather than estimated.
- The Exact Sciences purchase price allocation is described in the 10-Q as preliminary, and the filing states that differences between the preliminary and final allocation could be material. The goodwill, intangible assets and deferred tax amounts on the June 30, 2026 balance sheet may change as the valuation is completed, which would also change future amortization.
- The trailing-twelve-month block is a roll-forward, not a reported period. Its diluted EPS in particular rests on an implied weighted average share count rather than one Abbott published, and small differences from a figure computed a different way should be expected.
- The June 30, 2026 balance sheet and all 2026 quarterly figures are unaudited and condensed, as the 10-Q states.
Company details
| Value | |
|---|---|
| Name | Abbott Laboratories |
| Ticker | ABT |
| CIK | 0000001800 |
| Exchange | NYSE |
| State | Illinois |
| Incorporation | Illinois |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
Fiscal period
| FY2026 | |
|---|---|
| Fiscal year | 2026 |
| Fiscal period | Q2 |
| Tag | FY26Q2 |
| Period end | 2026-06-30 |
| Form | 10-Q |
| Accession | 0001628280-26-050134 |
| Fiscal year end | 1231 |
| Source | derived |
Source filings
| Role | Current | Form | Fiscal year | Fiscal period | Tag | Period end | Filed | Accession | Url | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| annual | no | 10-K | 2025 | FY | FY25 | 2025-12-31 | 2026-02-20 | 0001628280-26-010185 | https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm | reported |
| quarterly | yes | 10-Q | 2026 | Q2 | FY26Q2 | 2026-06-30 | 2026-07-28 | 0001628280-26-050134 | https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm | derived |
FAQ · Abbott Laboratories financial statements
How much revenue did Abbott report in Q2 FY2026?
Abbott Laboratories reported $12.59 billion in net sales for Q2 FY2026, the quarter ended June 30, 2026. That is up 13.0% from $11.14 billion in the same quarter a year earlier, growth that includes the Exact Sciences business acquired in March 2026.
What was Abbott's earnings per share in Q2 FY2026?
Abbott Laboratories reported diluted earnings per share of $0.53 for Q2 FY2026, the quarter ended June 30, 2026, against $1.01 in the same quarter a year earlier. Net earnings for the quarter were $928 million, down 47.8%.
Why did Abbott's profit fall in Q2 FY2026?
Abbott Laboratories earned $928 million in Q2 FY2026, down 47.8% from $1.78 billion a year earlier, even though net sales rose. Operating earnings were $1.69 billion, down 17.5%, held back by intangible amortization and integration expense from the Exact Sciences acquisition and by higher legal reserves, and the rest of the decline came below the operating line from interest on the acquisition debt and a higher tax charge.
How much did Abbott's Medical Devices segment sell in Q2 FY2026?
Abbott Laboratories' Medical Devices segment, its largest business, had net sales of $5.85 billion in Q2 FY2026, the quarter ended June 30, 2026, up 9.0% from $5.37 billion a year earlier.
Where can I get Abbott Laboratories (ABT) financial data in machine-readable form?
Ticker Scout publishes Abbott Laboratories's financial statements as JSON at https://tickerscout.ai/abt/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/abt/narrative.md and https://tickerscout.ai/abt/events.md. Abbott Laboratories's SEC CIK is 0000001800. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Abbott Laboratories (ABT) next file with the SEC?
Abbott Laboratories (ABT) is expected to file its next Form 10-Q with the SEC on or around October 28, 2026. That date is a projection rather than a company-announced date: it is derived from Abbott Laboratories's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-30, SEC accession 0001628280-26-050134.
Related companies
How this page was built
This page was built from two of Abbott Laboratories's own filings with the SEC, read one at a time. Nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names four such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Built from Abbott Laboratories's SEC filings by Ticker Scout; accession numbers are cited throughout so every figure can be checked against sec.gov. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.